Assay Corporate Finance successfully advised CooperSurgical, a leading provider of women’s health care solutions, on the acquisition of The Pipette Company (“TPC”) of Adelaide Australia.
A foremost manufacturer and distributor of micro pipettes for the ART market, TPC’s line of high quality products developed specifically for micromanipulation and IVF applications will be integrated into CooperSurgical’s world leading ART company ORIGIO. With TPC’s product lineup, ORIGIO will enhance its already strong pipette offering improving its position to meet the needs of customers within the ART segment.
“The Pipette Company’s innovative line of micro pipettes is a perfect fit with our ORIGIO (Humagen) pipette offering enhancing ORIGIO’s mission to provide world-class solutions for ART professionals” said Paul Remmell, President and CEO of CooperSurgical. “Providing customers with the highest quality micromanipulation products they require is the catalyst for enhancing our ART portfolio” added Remmell.
Since its founding in 1990, CooperSurgical has researched, developed and manufactured a wide range of trusted brands that have advanced the standard of women’s health care. CooperSurgical products are used by physicians and health care professionals in hospitals and their practices for a wide variety of procedures from basic annual gynecological exams to complex surgeries.
CooperSurgical Inc., is a wholly owned subsidiary of The Cooper Companies (NYSE: COO). The company, headquartered in Trumbull, CT produces and markets a wide array of products for use by women’s health care clinicians. More information can be found at www.coopersurgical.com
The Pipette Company